Evidence map›Paper›PMID 40143908›Full record

ArticleJHLT open2024

Donor-derived cell-free DNA, gene expression profile, and acute rejection in donation after circulatory death (DCD) heart transplant recipients.

Quan M Bui, Yan Gernhofer, Antoinette S Birs, Elizabeth Silver, Alessia Argiro, Benjamin Cruz, Eric Adler, Mark Kearns, Marcus A Urey, Victor Pretorius

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHLT open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Quan M BuiDivision of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Yan GernhoferUniversity of the Incarnate Word School of Osteopathic Medicine, San Antonio, Texas.
Antoinette S BirsDivision of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Elizabeth SilverDivision of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Alessia ArgiroCardiomyopathy Unit, University of Florence, Florence, Italy.
Benjamin CruzDivision of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Eric AdlerDivision of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Mark KearnsDivision of Cardiovascular and Thoracic Surgery, Department of Surgery, University of California, San Diego, La Jolla, California.
Marcus A UreyDivision of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Victor PretoriusDivision of Cardiovascular and Thoracic Surgery, Department of Surgery, University of California, San Diego, La Jolla, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Acute rejection (AR) is a leading cause of early morbidity and mortality in heart transplant (HTx) recipients. There is limited data on donation after circulatory death (DCD) HTx recipients where ischemia reperfusion injury may contribute to the development of AR and may be detected early with noninvasive biomarkers, such as donor-derived cell-free DNA (dd-cfDNA) and gene expression profile (GEP). The goal of this study is to compare dd-cfDNA, GEP, and rejection outcomes in DCD and donation after brain death (DBD) HTx recipients. Methods: This single-center, retrospective study included DCD and DBD HTx recipients from January 2020 to September 2022. Patients were excluded from the study if dd-cfDNA and GEP were not available. The CareDx HeartCare platform was used to obtain dd-cfDNA (AlloSure-Heart) and GEP (AlloMap) with the highest values for each patient recorded at 6 and 12 months. The mean values for these noninvasive markers were compared between DCD and DBD groups. Patients were followed for clinical outcomes, including treated AR, cardiac allograft vasculopathy (CAV), and death, through September 2023. Results: A total of 156 HTx patients were included with 50 DCD and 106 DBD recipients. Baseline characteristics were similar between DCD and DBD recipients including mean age (58.5 vs 56.9 years, Conclusions: In this single-center study, there were no significant differences in mean dd-cfDNA and treated AR at 1 year between DCD and DBD HTx recipients. There was a significant increase in mean GEP at 6 months, but not at 12 months in the DBD cohort. Overall, there does not appear to be clinically significant cardiac allograft injury related to DCD as measured by noninvasive markers. Further work is needed to confirm these findings.

Indexed as

acute rejectiondonation after circulatory deathdonor-derived cell-free DNAgene expression profileheart transplant

Identifiers

PMID40143908
PMCPMC11935317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.